Beta Bionics Wins Readers & #039; Choice for Medtech Company of the Year
The people have spoken. Beta Bionics has been named medtech company of the year. Nearly 44% of MD+DI readers participating in a special poll voted for the Boston, MA-based company, which is developing an artificial intelligence-powered bionic pancreas, called the iLet, to help manage type 1 diabetes. Beta Bionics pulled ahead of other competitors like Boston Scientific, which was MD+DI Editorâs Choice for medtech company of the year.
Each year, MD+DI's editors take a long, hard look at the medical device and diagnostics companies that rose above the ranks over the past 12 months. It can be savvy business strategies, breakthrough products, or operational execution that set the best of the best apart.
Beta Bionics has been making significant strides in the diabetes management landscape by scoring an IDE and a plush partnership with Senseonics Holdings.
âThis is really is a cherry on top of a wonderful cake that weâve had which is 2018,â Edward Raskin, vice president of business development and a board member at Beta Bionics, told MD+DI. âThis is the year weâve been recognized by the industry along with the community and have been in clinical trials doing our working studies as we lead into our pivotal trials in 2019. This is just an incredible feeling to march through so many achievements.â
Beta Bionicsâs iLet consists of a dual-chamber...
Source: MDDI - Category: Medical Devices Authors: Omar Ford Tags: Digital Health Source Type: news
More News: Clinical Trials | Diabetes | Diabetes Type 1 | Endocrinology | Hormones | Insulin | Learning | Legislation | Medical Devices | Nurses | Nursing | Pancreas | Partnerships | Study | Universities & Medical Training